|
Our strategy is to retain critical in-house resource whilst out-sourcing and partnering with leading companies and institutions to provide flexibility, manage risk and maximise value. We have forged effective relationships with academic groups, clinicians and regulatory agencies.
Our partners include sanofi-aventis, Sigma-Aldrich, Wyeth and charitable organisations, such as the Foundation Fighting Blindness and the UK Motor Neurone Disease Association. Our LentiVector technology is used extensively in drug discovery and has been licensed to leading pharmaceutical and biopharmaceutical companies, including Biogen Idec, GlaxoSmithKline, Merck & Co, and Pfizer, for their own research activities.
Our in-house capabilities span research, clinical development, regulatory affairs and manufacturing. At the end of 2008, our staff numbered 76, mainly based in laboratories and offices in Oxford. We also have a wholly owned subsidiary, BioMedica Inc, based in San Diego, USA.
We maintain the highest standards of integrity in our dealings with all parties, including shareholders, employees, patients, healthcare professionals, partners, and licensees. Through scientific, commercial and operational excellence, we aim to maximise returns for shareholders.
Oxford BioMedica is a member of the UK BioIndustry Association and the US Biotechnology Industry Organization.
|
 |
|
